The Expanding IBD Toolbox: Targeting TL1A
Release Date: January 30, 2026
Expiration Date: January 30, 2027
Time to Complete Activity: 1.0 hour
Faculty
Millie D. Long, MD, MPH, FACG—ChairpersonProfessor of Medicine
Chief, Division of Gastroenterology and Hepatology
University of North Carolina at Chapel Hill
Chapel Hill, NC
Jessica R. Allegretti, MD, MPH, FACG, AGAF
Medical Director, Infusion Services
Director, Crohn’s and Colitis Center
Director of Clinical Research
Director, Fecal Microbiota Transplant Program
Division of Gastroenterology, Hepatology and Endoscopy
Brigham and Women’s Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, MA
Bruce E. Sands, MD, MS
Dr Burrill B. Crohn Professor of Medicine
Icahn School of Medicine at Mount Sinai
System Chief, Division of Gastroenterology
Mount Sinai Health System
New York, NY
Target Audience
This activity has been designed to meet the educational needs of gastroenterology clinicians, including MDs, DOs, nurse practitioners, and PAs. It may also benefit primary care providers and other clinicians who are interested in the management of patients with inflammatory bowel disease (IBD).
Educational Provider
This activity is provided by Paradigm Medical Communications, LLC. 
Supporter Acknowledgment
This activity is supported by an educational grant from Genentech, a member of the Roche Group.Program Overview
Despite an expanding array of advanced therapies for IBD, many patients with moderate to severe disease remain refractory to current options. Anti-tumor necrosis factor-like ligand 1A (TL1A) agents represent a promising new class targeting TL1A, a cytokine implicated in IBD pathogenesis. Experts review the current landscape and contextualize emerging data that suggest TL1A blockade may deliver meaningful clinical outcomes. As late-phase trials progress, clinicians should stay informed on this novel mechanism of action and its potential role in personalized treatment strategies for IBD.
Learning Objectives
Upon completion of this activity, participants should be able to:- Describe the immune pathophysiology of IBD
- Outline mechanisms of action and new data of investigational agents for IBD, including those that target TL1A
Physician Accreditation Statement
Paradigm Medical Communications, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.Physician Credit Designation Statement
Paradigm Medical Communications, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.PA Continuing Education
PAs may claim a maximum of 1.0 Category 1 credit for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.Nurse Practitioner Continuing Education
The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.Hardware/Software Requirements
This accredited CME activity is designed using HTML5 web components. As you navigate the video using the supplied controls, the slides will sync to the speaker.Supported Browsers (Desktop/Mobile)
Chrome 45+, Firefox 40+, Edge, Edge Chromium, Safari 8+, Opera 31+
PDF documents
This activity may contain PDF documents. Most current browsers support viewing of PDFs natively, but you may also download a free version of Adobe Acrobat Reader here: http://get.adobe.com/reader
Technical Support: If you have any technical problems or playback issues, email us at contactus@paradigmmc.com.
Instructions for Participation
To receive a certificate and claim credit, participants must:- Follow instructions to register or log in with your professional information and complete the pretest
- View the online activity in its entirety
- Complete and submit the online posttest and evaluation. You must answer 70% of the posttest questions correctly to earn credit. You will have unlimited opportunities to successfully complete the posttest
For questions regarding CME credit, contact the Paradigm CME Department at cme@paradigmmc.com.
There are no fees for participating in this activity.
Disclosure of Relevant Financial Relationships
In accordance with the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education, Paradigm requires that all planners, faculty, and others who are in a position to control the content of this activity disclose all financial relationships with ineligible companies during the past 24 months.All relevant relationships are identified and mitigated according to Paradigm policy prior to individuals assuming their roles and are disclosed prior to learners’ engagement in the activity. Paradigm is committed to providing learners with high-quality accredited continuing education that promotes improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The content of this activity was independently reviewed to ensure that it is fair and balanced, scientifically rigorous, evidence based, and aligned with the public interest. All relevant relationships have been mitigated.
Millie D. Long, MD, MPH, FACG
Consultant: AbbVie Inc.; Bristol-Myers Squibb Company; Celltrion Inc; F. Hoffmann-La Roche AG; Genentech, Inc.; Intercept Pharmaceuticals, Inc; Janssen Pharmaceuticals, Inc; Eli Lilly and Company; Merck & Co, Inc; Pfizer Inc; Prometheus Laboratories; Roivant Sciences Ltd.; Sanofi; Spyre Therapeutics, Inc.; Takeda Pharmaceutical Company Ltd; Target RWE
Research Funding: Celltrion Inc; Eli Lilly and Company; Pfizer Inc; Takeda Pharmaceutical Company Ltd
Jessica R. Allegretti, MD, MPH, FACG, AGAF
Consultant: AbbVie, Inc.; Bristol-Myers Squibb Company; Celltrion Inc; Curogen Technology; Ferring Pharmaceuticals; Genentech, Inc.; GlaxoSmithKline; Janssen Pharmaceuticals, Inc; Merck & Co, Inc; Metagen Therapeutics, Inc.; Pfizer Inc; Roivant Sciences Ltd.; Seres Therapeutics; Shattuck Labs, Inc; TRXBio Co., Ltd; Vendanta Biosciences, Inc.; Xencor
Speakers Bureau: AbbVie, Inc.; Janssen Pharmaceuticals, Inc
Bruce E. Sands, MD, MS
Consultant: AbbVie, Inc.; Amgen Inc; AstraZeneca; Boehringer Ingelheim International GmbH; Bristol-Myers Squibb Company; Celltrion Inc; Ferring Pharmaceuticals; Galapagos NV; Genentech, Inc.; Gilead Sciences, Inc.; GlaxoSmithKline; Janssen Pharmaceuticals, Inc; Johnson & Johnson Innovative Medicine; Merck & Co, Inc; Pfizer Inc; Sanofi; Takeda Pharmaceutical Company Ltd; Teva Pharmaceutical Industries Ltd
Research Funding: Janssen Pharmaceuticals, Inc
Stocks: Ventyx Biosciences, Inc
Paradigm Medical Communications, LLC staff members have no relevant financial relationships with ineligible companies to disclose.
Independent peer reviewer has no relevant financial relationships with ineligible companies to disclose.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the FDA.Disclaimer
This CME activity represents the views and opinions of the individual faculty, and does not constitute the opinion or endorsement of, or promotion by, Paradigm Medical Communications, LLC. Reasonable efforts have been taken to present educational subject matter in a balanced, unbiased fashion, and in compliance with regulatory requirements. However, each activity participant must always use his or her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.If included, signed statements of informed consent granting permission for publication have been obtained for all photographs and videos in which an individual can be identified.
As an ACCME-accredited provider, Paradigm Medical Communications, LLC must ensure that its activities include a balanced view of therapeutic options. Use of generic names contributes to this impartiality. The use of trade names should not be viewed as an endorsement of specific products by Paradigm Medical Communications, LLC.
Terms of Use and Privacy Policy
Disclaimer
The materials provided for this activity are for informational purposes only and should not be used for diagnosis or treatment of a health problem without consulting a licensed medical professional. This CME activity represents the views and opinions of the individual faculty, and does not constitute the opinion or endorsement of, or promotion by, Paradigm Medical Communications, LLC. References to any entity, product, service, or source of information on this website should not be considered an endorsement, either direct or implied, by Paradigm Medical Communications, LLC. Paradigm Medical Communications, LLC accepts no liability for the content referenced in this activity.
Privacy policy
Paradigm Medical Communications, LLC or hosted contracted partner is committed to protecting the privacy of those who participate in the activities located at www.paradigmmc.com (herein referred to as “website”). The information below describes the security of the website for safeguarding personal information and the rationale for collection and use of personal information.
Security/safeguarding personal information
This website has physical and procedural safeguards in place to prevent unauthorized access to personal information used to access this website.
Collection and use of your personal information
The submission of certain personally identifiable information is necessary to award and track the credits participants may earn after completing the program and may be used to track registration and participation. Required items include first name, last name, degree, and email address. These items are necessary. Participants are also required to complete an evaluation of the CME activity. All evaluative information submitted is collected and retained, and used by Paradigm Medical Communications, LLC to continuously improve the learning experience.
Paradigm Medical Communications, LLC does not otherwise transfer, sell, or share personal information with outside parties. Paradigm Medical Communications, LLC will not otherwise disclose personal information unless required to in a legal process. Paradigm Medical Communications, LLC staff members review individual test results to the extent necessary to record and track participants’ credits.
Contact Us
If you have any questions or comments, please email us at contactus@paradigmmc.com.© 2026 Paradigm Medical Communications, LLC except where noted. Content may not be reproduced in whole or part without the express written permission of Paradigm Medical Communications, LLC.